表紙
市場調査レポート

インクレチン製剤:糖尿病治療薬の市場と治療薬の開発

Incretin-Based Drugs: Markets for Diabetes Therapies and Developing Treatments

発行 BCC Research 商品コード 324910
出版日 ページ情報 英文 136 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.12円で換算しております。
Back to Top
インクレチン製剤:糖尿病治療薬の市場と治療薬の開発 Incretin-Based Drugs: Markets for Diabetes Therapies and Developing Treatments
出版日: 2015年02月25日 ページ情報: 英文 136 Pages
担当者のコメント
BCC Research社のレポートは、Reuter、Wall Street Journal、Fortuneなどで引用されることも多く、それぞれの業界の識者の意見として重きを置かれています。同社レポートを複数冊ご購入の場合年間パッケージのご契約がお得です。詳細は右の担当者のおすすめ商品よりご覧下さい。
概要

世界のインクレチン製剤の市場は2013年に約118億ドル、2014年には約127億ドルの規模を記録しました。2014年から2019年にかけては12.4%のCAGRで推移し、2019年には228億ドルの規模に達すると予測されています。

当レポートでは、糖尿病治療のためのインクレチン製剤の市場について調査し、糖尿病および糖尿病治療の概要、上市済みインクレチン製剤およびパイプライン候補化合物の種類と概要、開発パイプラインの動向、インクレチン製剤の市場規模の推移と予測、市場成長への各種影響因子の分析、主要事業者のプロファイルなどをまとめています。

第1章 イントロダクション

第2章 エグゼクティブサマリー

  • インクレチンによる 血糖コントロール
  • 調剤および販売の動向

第3章 概要・市場予測

  • 標準的な糖尿病治療
    • メトホルミン
    • スルホニル尿素 (SU)
    • チアゾリジンジオン (TZD)
    • αグルコシダーゼ阻害薬
    • インスリン治療
      • 長時間作用型インスリン
      • 中時間作用型インスリン
      • 普通・短時間作用型インスリン
      • 速効型インスリン
    • その他の新しい治療法
  • 糖尿病の詳細解説
    • 糖尿病のタイプ
      • 1型
      • 2型
      • 妊娠性糖尿病
      • 耐糖能異常 (IGT)・空腹時血糖異常 (IFG)
    • インクレチンによるケアモデル
    • 糖尿病に関連する症状
      • 肥満
      • 心血管系疾病
      • 膵臓炎
      • 多嚢胞性卵巣症候群
    • 合併症・併存疾患
  • インクレチンによる治療
  • LP-1受容体作動薬
  • 上市済みGLP-1受容体アゴニスト
    • Exenatide
    • Liraglutide
    • Dulaglutide
    • Albiglutide
    • Lixisenatide
  • 上市済みDPP-4阻害剤
    • Linagliptin
    • Sitagliptin
    • Vildagliptin
    • Saxagliptin
    • Alogliptin
    • Teneligliptin
    • Anagliptin
    • Gemigliptin
  • 市場環境
  • インクレチン市場における契約

第4章 開発パイプライン

  • 法規制環境
  • 特許
  • 開発パイプライン
  • 開発中の主なGLP-1受容体アゴニスト
  • 開発中の主なDPP-4阻害剤
  • 開発ケーススタディ:PHENOMIX
  • 確実視されるパイプライン候補化合物・新しい研究
    • 新しいアクティブ薬剤候補
      • デュアルGLP-1/グルカゴンアゴニスト
      • グルカゴン受容体アゴニスト
      • GLP-2
      • GPR119
      • TGR5
      • グルコキナーゼ活性薬
    • その他新しい調査
      • Imperial College London
      • Orgenesis社
    • 開発環境:医薬品市場全体
    • 販売領域としての糖尿病
    • 生物製剤・GLP-1受容体アゴニストの製造
      • 成長因子
      • 遺伝子治療
      • 遺伝子組換えタンパク質
      • モノクローナル抗体
  • 生物製剤の環境
  • 糖尿病・糖尿病関連薬剤のパイプライン
  • 治療分野としての肥満

第5章 企業プロファイル

  • ACTIVX BIOSCIENCES INC. (キョーリン製薬)
  • AERPIO THERAPEUTICS INC.
  • AMPIO PHARMACEUTICALS INC.
  • AMUNIX
  • ARAIM PHARMACEUTICALS INC.
  • ARISAPH
  • ASTRAZENECA
  • BECTON, DICKINSON AND COMPANY
  • BOEHRINGER INGELHEIM GMBH
  • BRISTOL-MYERS SQUIBB
  • CEBIX INC.
  • CHEMOCENTRYX INC.
  • CODA THERAPEUTICS INC.
  • CONCERT PHARMACEUTICALS
  • CONJUCHEM
  • DIPEXIUM PHARMACEUTICALS INC.
  • DONG-A SOCIO HOLDINGS
  • ELI LILLY AND COMPANY
  • EMISPHERE TECHNOLOGIES INC.
  • EVOKE PHARMA INC.
  • FURIEX PHARMACEUTICALS INC.
  • GENKYOTEX S.A.
  • GLAXOSMITHKLINE PLC
  • GLYCADIA PHARMACEUTICALS
  • HANMI PHARMACEUTICAL CO. LTD.
  • ICO THERAPEUTICS INC.
  • INTARCIA THERAPEUTICS INC.
  • JOHNSON & JOHNSON
  • 興和
  • キョーリン製薬
  • 協和発酵キリン
  • LIGAND PHARMACEUTICALS INC.
  • LG LIFE SCIENCES LTD.
  • MANNKIND CORP.
  • MERCK
  • MERRION PHARMACEUTICALS LTD.
  • 田辺三菱製薬
  • NEPHROGENEX INC.
  • NOVARTIS INTERNATIONAL AG
  • NOVO NORDISK A/S
  • 小野薬品工業
  • ORAMED PHARMACEUTICALS
  • 大塚製薬
  • PFIZER
  • PHASEBIO PHARMACEUTICALS INC.
  • QUARK PHARMACEUTICALS INC.
  • ROCHE
  • ROYER BIOMEDICAL INC.
  • SANOFI
  • 三和化学研究所
  • SATRX LLC
  • SIHUAN PHARMACEUTICAL HOLDINGS GROUP CO. LTD.
  • 武田薬品工業
  • TRANSITION THERAPEUTICS INC.
  • TRANSTECH PHARMA LLC
  • VIKING THERAPEUTICS INC.
  • ZEALAND PHARMA A/S
  • ZOSANO PHARMA CORP.

図表一覧

目次
Product Code: PHM162A

REPORT HIGHLIGHTS

The global market for incretin-based therapeutics was valued at nearly $11.8 billion in 2013 and $12.7 billion in 2014. This market is expected to reach $22.8 billion by 2019, with a compound annual growth rate (CAGR) of 12.4% from 2014 to 2019.

This report provides:

  • An overview of the global diabetes treatment market.
  • Analyses of global market trends, with data from 2012 to 2014, and projections of CAGRs through 2019.
  • Information on the field of glucagon-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors collectively known as incretin-based therapies, a drug category used mainly for the control of diabetes but that also have potential indications for cardiovascular treatment and even weight loss.
  • Drug sales earned according to therapeutic area as well as by geography.
  • Analysis of the market's dynamics, specifically major issues, and challenges.
  • Relevant intellectual property (IP) and patent analysis.

SCOPE OF REPORT

The scope of this study encompasses companies that are involved in diabetes prevention as well as detection, diagnosis and treatment. BCC Research analyzes each technology or therapy type, determines its current market status, examines its impact on future markets and presents forecasts of growth over the next five years. Technological issues, including the latest trends, are discussed.

ANALYST'S CREDENTIALS

Kim Lawson is a graduate of Mount Holyoke College with a degree in English Literature and a M.A in management from Harvard University's extension program. She acquired experience as a healthcare journalist, including working for John Wiley & Sons as a print reporter, before serving as a research analyst in a small market research firm in the Research Triangle Park area of North Carolina and which focused on pharmaceuticals and biotechnology. Before joining that firm, Lawson published two reports on emerging and established diagnostics and therapeutics for benign and cancerous breast disease.

Table of Contents

CHAPTER 1 - INTRODUCTION

  • STUDY GOALS AND OBJECTIVES
  • REASONS FOR DOING THIS STUDY
  • SCOPE OF REPORT
  • INTENDED AUDIENCE
  • METHODOLOGY
  • INFORMATION SOURCES
  • ANALYST'S CREDENTIALS
  • RELATED BCC RESEARCH REPORTS
  • BCC RESEARCH WEBSITE
  • DISCLAIMER

CHAPTER 2 - EXECUTIVE SUMMARY

  • INCRETINS FILL NEED FOR GLYCEMIC CONTROL
  • TRENDS IN DISPENSING AND SALES
  • SUMMARY TABLE: GLOBAL MARKET FOR INCRETIN-BASED THERAPEUTICS, THROUGH 2019 ($ MILLIONS)
  • SUMMARY FIGURE: GLOBAL MARKET FOR INCRETIN-BASED THERAPEUTICS, 2012-2019 ($ MILLIONS)
    • GEOGRAPHICAL SHIFTS
    • KEY DRIVERS
    • KEY CHALLENGES
    • KEY TRENDS

CHAPTER 3 - OVERVIEW AND MARKET FORECAST

  • FIGURE 1: THE INCRETIN EFFECT ILLUSTRATED
  • FIGURE 2: PERCENTAGE OF DISPENSED PRESCRIPTIONS FOR NON-INSULIN ANTIDIABETICS, 2012 (%)
    • DATA ON WHERE INCRETINS FIT
      • FIGURE 3: PERCENTAGE OF DISPENSED PRESCRIPTIONS FOR GLP-1 RECEPTOR AGONISTS, 2012 (%)
      • FIGURE 4: PERCENTAGE OF DISPENSED PRESCRIPTIONS FOR DPP-4 INHIBITORS, 2012 (%)
    • FOR SOME, A GLP-1 FOCUS
      • TABLE 1: DIFFERENCES BETWEEN THE INCRETIN THERAPIES
  • STANDARD DIABETIC TREATMENTS
    • METFORMIN
    • SULFONYLUREAS (SU)
    • THIAZOLIDINEDIONE (TZD)
    • ALPHA-GLUCOSIDASE INHIBITORS
    • INSULIN TREATMENT
      • Long-acting Insulin
      • Intermediate-acting Insulin
      • Regular or Short-acting Insulin
      • Rapid-acting Insulin
        • TABLE 2: ADVANTAGES TO ADDING INCRETIN THERAPY
    • OTHER NEW TREATMENTS
  • DIABETES FURTHER EXPLAINED
    • TYPES OF DIABETES
      • Type 1
      • Type 2
      • Gestational Diabetes
      • Impaired Glucose Tolerance (IGT) and Impaired Fasting Glycemia (IFG)
    • CARE MODEL UPDATED WITH INCRETINS
    • CONDITIONS RELATED TO DIABETES
      • Obesity
        • FIGURE 5: ADA'S STANDARD OF MEDICAL CARE IN DIABETES, 2014
      • Cardiovascular Disease
      • Pancreatitis
      • Cancer
        • TABLE 3: CURRENT THINKING ON DIABETES MEDICATIONS AND CANCER RISK
      • Polycystic Ovary Syndrome
    • COMPLICATIONS AND COMORBIDITIES
      • TABLE 4: COMPLICATIONS/COMORBID CONDITIONS FROM DIABETES
  • INCRETIN THERAPIES
    • TABLE 5: COMMERCIALIZED INCRETIN THERAPY
  • GLP-1 RECEPTOR AGONISTS
  • COMMERCIALIZED GLP-1 RECEPTOR AGONISTS
    • Exenatide
    • Liraglutide
    • Dulaglutide
    • Albiglutide
    • Lixisenatide
  • COMMERCIALIZED DPP-4 INHIBITORS
    • Linagliptin
    • Sitagliptin
    • Vildagliptin
    • Saxagliptin
    • Alogliptin
    • Teneligliptin
    • Anagliptin
    • Gemigliptin
  • MARKET LANDSCAPE
    • TABLE 6: NUMBER OF COMMERCIALIZED INCRETIN-BASED THERAPEUTICS, 2014 AND 2019 (UNITS)
    • FIGURE 6: NUMBER OF COMMERCIALIZED INCRETIN-BASED THERAPEUTICS, 2014 AND 2019 (UNITS)
    • FIGURE 7: MARKET SHARE OF INCRETIN-BASED THERAPEUTICS, BY THERAPEUTIC AREA, 2014 AND 2019 (% OF REVENUE BY THERAPEUTIC AREA)
    • FIGURE 8: MARKET SHARE OF COMMERCIALIZED INCRETIN-BASED THERAPEUTICS, BY INCRETIN TYPE, 2014 AND 2019 (% OF REVENUE BY INCRETIN TYPE)
    • FIGURE 9: MARKET SHARE OF COMMERCIALIZED GLP-1 RECEPTOR AGONISTS, BY DOSING FREQUENCY, 2014 AND 2019 (%)
  • DEALS IN THE INCRETIN MARKET
    • TABLE 7: MAJOR AGREEMENTS FOR INCRETIN-BASED THERAPY DEVELOPMENT

CHAPTER 4 - THE DEVELOPMENT PIPELINE

  • REGULATORY ENVIRONMENT
  • PATENTS
  • DEVELOPMENT PIPELINE
    • FIGURE 10: NUMBER OF INCRETINS IN DEVELOPMENT BY PHASE, 2014
  • KEY GLP-1 RECEPTOR AGONISTS IN DEVELOPMENT
    • Exenatide Formulations (Including ICTA,
    • VRS-859/Exenatide-extended Release, and Microsphere Formulation of Exenatide, DA-3091)
    • Liraglutide for Obesity (Sandexa) and for Type 1 Diabetes (NN9211)
    • Lixisenatide (Lyxumia and LixiLan [Combined Lixisenatide and Basal Insulin])
    • Semaglutide (NN9535)
    • CJC-1134-PC
      • TABLE 8: GLP-1 RECEPTOR AGONISTS IN LATE-STAGE DEVELOPMENT
      • TABLE 9: GLP-1 RECEPTOR AGONISTS IN EARLY-STAGE DEVELOPMENT
  • KEY DPP-4 INHIBITORS IN DEVELOPMENT
    • Saxagliptin (Onglyza/)Dapagliflozin Combination (Forxiga)
    • Trelagliptin
    • Omarigliptin
    • Gosogliptin (Satyor)
    • Gemigliptin
      • TABLE 10: DPP-4 INHIBITORS IN LATE-STAGE DEVELOPMENT
      • TABLE 11: DPP-4 INHIBITORS IN EARLY-STAGE DEVELOPMENT
  • DEVELOPMENT CASE STUDY: PHENOMIX
  • PROMISING PIPELINE CANDIDATES AND NOVEL RESEARCH
    • NOVEL ACTIVE DRUG CANDIDATES
      • Dual GLP-1/Glucagon Agonists
      • Glucagon Receptor Agonists
      • GLP-2
      • GPR119
      • TGR5
      • Glucokinase Activators
    • OTHER NOVEL RESEARCH
      • Department of Medicine, Imperial College London, U.K.
      • Orgenesis' Conversion of Liver Cells
    • DEVELOPMENT LANDSCAPE: OVERALL PHARMA MARKET
      • TABLE 12: TOP PHARMA COMPANIES BY REVENUE, 2013 ($ BILLIONS)
      • FIGURE 11: GEOGRAPHIC DISTRIBUTION OF PHARMACEUTICAL DRUGS, 2012 AND 2017 (PERCENT OF GLOBAL SALES)
    • DIABETES AS SALES TERRITORY
      • FIGURE 12: DIABETES-FOCUSED GEOGRAPHIC TERRITORY: NOVO NORDISK SALES, 2013 (% OF SALES)
    • BIOLOGICS AND GLP-1 RECEPTOR AGONIST PRODUCTION
      • Growth Factors
      • Gene Therapy
      • Recombinant Proteins
      • Monoclonal Antibodies
  • BIOLOGIC LANDSCAPE
    • TABLE 13: BIOLOGICS IN DEVELOPMENT IN THE U.S. BY THERAPEUTIC CATEGORY, 2013
  • PIPELINE FOR DIABETES AND DIABETES-RELATED MEDICATIONS
    • TABLE 14: GLOBAL PIPELINE FOR PHASE II AND III STAGE DIABETES MEDICATIONS, THROUGH 2019
    • TABLE 15: GLOBAL PIPELINE FOR PHASE I STAGE DIABETES MEDICATIONS, THROUGH 2019
    • TABLE 16: GLOBAL PIPELINE FOR DIABETES-RELATED DISORDERS, THROUGH 2019
  • OBESITY AS THERAPEUTIC CATEGORY
    • TABLE 17: GLOBAL PIPELINE FOR OBESITY, THROUGH 2019
    • TABLE 18: DIABETES AND DRUG DEVELOPMENT RESOURCES

CHAPTER 5 - COMPANY PROFILES

  • ACTIVX BIOSCIENCES INC. (KYORIN PHARMACEUTICAL CO. LTD.)
  • AERPIO THERAPEUTICS INC.
  • AMPIO PHARMACEUTICALS INC.
  • AMUNIX
  • ARAIM PHARMACEUTICALS INC.
  • ARISAPH
  • ASTRAZENECA
  • BECTON, DICKINSON AND COMPANY
  • BOEHRINGER INGELHEIM GMBH
  • BRISTOL-MYERS SQUIBB
  • CEBIX INC.
  • CHEMOCENTRYX INC.
  • CODA THERAPEUTICS INC.
  • CONCERT PHARMACEUTICALS
  • CONJUCHEM
  • DIPEXIUM PHARMACEUTICALS INC.
  • DONG-A SOCIO HOLDINGS
  • ELI LILLY AND COMPANY
  • EMISPHERE TECHNOLOGIES INC.
  • EVOKE PHARMA INC.
  • FURIEX PHARMACEUTICALS INC.
  • GENKYOTEX S.A.
  • GLAXOSMITHKLINE PLC
  • GLYCADIA PHARMACEUTICALS
  • HANMI PHARMACEUTICAL CO. LTD.
  • ICO THERAPEUTICS INC.
  • INTARCIA THERAPEUTICS INC.
  • JOHNSON & JOHNSON
  • KOWA CO. LTD.
  • KYORIN PHARMACEUTICAL CO. LTD.
  • KYOWA HAKKO KIRIN CO. LTD.
  • LIGAND PHARMACEUTICALS INC.
  • LG LIFE SCIENCES LTD.
  • MANNKIND CORP.
  • MERCK
  • MERRION PHARMACEUTICALS LTD.
  • MITSUBISHI TANABE PHARMA CORP.
  • NEPHROGENEX INC.
  • NOVARTIS INTERNATIONAL AG
  • NOVO NORDISK A/S
  • ONO PHARMACEUTICALS
  • ORAMED PHARMACEUTICALS
  • OTSUKA PHARMACEUTICAL CO. LTD.
  • PFIZER
  • PHASEBIO PHARMACEUTICALS INC.
  • QUARK PHARMACEUTICALS INC.
  • ROCHE
  • ROYER BIOMEDICAL INC.
  • SANOFI
  • SANWA KAGAKU KENKYUSHO CO. LTD.
  • SATRX LLC
  • SIHUAN PHARMACEUTICAL HOLDINGS GROUP CO. LTD.
  • TAKEDA PHARMACEUTICAL CO. LTD.
  • TRANSITION THERAPEUTICS INC.
  • TRANSTECH PHARMA LLC
  • VIKING THERAPEUTICS INC.
  • ZEALAND PHARMA A/S
  • ZOSANO PHARMA CORP.

LIST OF TABLES

  • SUMMARY TABLE GLOBAL MARKET FOR INCRETIN-BASED THERAPEUTICS, THROUGH 2019 ($ MILLIONS)
    • TABLE 1: DIFFERENCES BETWEEN THE INCRETIN THERAPIES
    • TABLE 2: ADVANTAGES TO ADDING INCRETIN THERAPY
    • TABLE 3: CURRENT THINKING ON DIABETES MEDICATIONS AND CANCER RISK
    • TABLE 4: COMPLICATIONS/COMORBID CONDITIONS FROM DIABETES
    • TABLE 5: COMMERCIALIZED INCRETIN THERAPY
    • TABLE 6: NUMBER OF COMMERCIALIZED INCRETIN-BASED THERAPEUTICS, 2014 AND 2019 (UNITS)
    • TABLE 7: MAJOR AGREEMENTS FOR INCRETIN-BASED THERAPY DEVELOPMENT
    • TABLE 8: GLP-1 RECEPTOR AGONISTS IN LATE-STAGE DEVELOPMENT
    • TABLE 9: GLP-1 RECEPTOR AGONISTS IN EARLY-STAGE DEVELOPMENT
    • TABLE 10: DPP-4 INHIBITORS IN LATE-STAGE DEVELOPMENT
    • TABLE 11: DPP-4 INHIBITORS IN EARLY-STAGE DEVELOPMENT
    • TABLE 12: TOP PHARMA COMPANIES BY REVENUE, 2013 ($ BILLIONS)
    • TABLE 13: BIOLOGICS IN DEVELOPMENT IN THE U.S. BY THERAPEUTIC CATEGORY, 2013
    • TABLE 14: GLOBAL PIPELINE FOR PHASE II AND III STAGE DIABETES MEDICATIONS, THROUGH 2019
    • TABLE 15: GLOBAL PIPELINE FOR PHASE I STAGE DIABETES MEDICATIONS, THROUGH 2019
    • TABLE 16: GLOBAL PIPELINE FOR DIABETES-RELATED DISORDERS, THROUGH 2019
    • TABLE 17: GLOBAL PIPELINE FOR OBESITY, THROUGH 2019
    • TABLE 18: DIABETES AND DRUG DEVELOPMENT RESOURCES

LIST OF FIGURES

  • SUMMARY FIGURE GLOBAL MARKET FOR INCRETIN-BASED THERAPEUTICS, 2012-2019 ($ MILLIONS)
    • FIGURE 1: THE INCRETIN EFFECT ILLUSTRATED
    • FIGURE 2: PERCENTAGE OF DISPENSED PRESCRIPTIONS FOR NON-INSULIN ANTIDIABETICS, 2012 (%)
    • FIGURE 3: PERCENTAGE OF DISPENSED PRESCRIPTIONS FOR GLP-1 RECEPTOR AGONISTS, 2012 (%)
    • FIGURE 4: PERCENTAGE OF DISPENSED PRESCRIPTIONS FOR DPP-4 INHIBITORS, 2012 (%)
    • FIGURE 5: ADA'S STANDARD OF MEDICAL CARE IN DIABETES, 2014
    • FIGURE 6: NUMBER OF COMMERCIALIZED INCRETIN-BASED THERAPEUTICS, 2014 AND 2019 (UNITS)
    • FIGURE 7: MARKET SHARE OF INCRETIN-BASED THERAPEUTICS, BY THERAPEUTIC AREA, 2014 AND 2019 (% OF REVENUE BY THERAPEUTIC AREA)
    • FIGURE 8: MARKET SHARE OF COMMERCIALIZED INCRETIN-BASED THERAPEUTICS, BY INCRETIN TYPE, 2014 AND 2019 (% OF REVENUE BY INCRETIN TYPE)
    • FIGURE 9: MARKET SHARE OF COMMERCIALIZED GLP-1 RECEPTOR AGONISTS, BY DOSING FREQUENCY, 2014 AND 2019 (%)
    • FIGURE 10: NUMBER OF INCRETINS IN DEVELOPMENT BY PHASE, 2014
    • FIGURE 11: GEOGRAPHIC DISTRIBUTION OF PHARMACEUTICAL DRUGS, 2012 AND 2017 (PERCENT OF GLOBAL SALES)
    • FIGURE 12: DIABETES-FOCUSED GEOGRAPHIC TERRITORY: NOVO NORDISK SALES, 2013 (% OF SALES)
Back to Top